Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
15 01 2019
Historique:
received: 06 07 2018
accepted: 24 10 2018
pubmed: 2 11 2018
medline: 23 10 2019
entrez: 2 11 2018
Statut: epublish

Résumé

Drug resistance remains a major concern for human immunodeficiency virus (HIV) treatment. To date, very few resistance mutations have emerged in first-line combination therapy that includes the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG).

Identifiants

pubmed: 30381490
pii: JVI.01189-18
doi: 10.1128/JVI.01189-18
pmc: PMC6321921
pii:
doi:

Substances chimiques

HIV Integrase Inhibitors 0
Heterocyclic Compounds, 3-Ring 0
Oxazines 0
Piperazines 0
Pyridones 0
RNA, Viral 0
dolutegravir DKO1W9H7M1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : NIH HHS
ID : P51 OD011107
Pays : United States

Informations de copyright

Copyright © 2019 American Society for Microbiology.

Références

Antimicrob Agents Chemother. 1997 Feb;41(2):278-83
pubmed: 9021180
Antivir Ther. 2017;22(2):93-95
pubmed: 27977411
BMC Med. 2013 Nov 22;11:249
pubmed: 24267867
J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):124-34
pubmed: 15671796
J Antimicrob Chemother. 2016 Jul;71(7):1948-53
pubmed: 27029845
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28923862
J Virol. 2012 Mar;86(5):2696-705
pubmed: 22205735
J Infect Dis. 2017 Dec 1;216(suppl_9):S843-S846
pubmed: 28968669
J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19518
pubmed: 25394027
PLoS One. 2017 Jul 28;12(7):e0181357
pubmed: 28753637
J Virol. 2015 Dec;89(23):12002-13
pubmed: 26378179
Lab Anim (NY). 2017 May 22;46(6):259-270
pubmed: 28530684
Antivir Ther. 2012;17(6):941-53
pubmed: 22898622
Antivir Ther. 2017;22(2):169-172
pubmed: 27588613
Antimicrob Agents Chemother. 1996 Nov;40(11):2586-91
pubmed: 8913470
J Infect Dis. 2018 Jul 24;218(5):688-697
pubmed: 29617822
J Virol. 2004 May;78(10):5324-37
pubmed: 15113912
J Virol. 2014 Feb;88(4):2011-24
pubmed: 24307581
J Virol. 2014 Sep 1;88(17):9683-92
pubmed: 24920794
Lancet HIV. 2017 Dec;4(12):e547-e554
pubmed: 29107562
Sci Transl Med. 2018 May 2;10(439):
pubmed: 29720451
Br J Clin Pharmacol. 2015 Sep;80(3):502-14
pubmed: 25819132
Nature. 2014 Aug 7;512(7512):74-7
pubmed: 25042999
J Antimicrob Chemother. 2017 Sep 1;72(9):2570-2573
pubmed: 28637235
Antimicrob Agents Chemother. 2013 Jun;57(6):2654-63
pubmed: 23529738
J Infect Dis. 2017 Dec 1;216(suppl_9):S851-S856
pubmed: 29207000
J Antimicrob Chemother. 2016 Jul;71(7):1975-81
pubmed: 27021341
J Virol. 2006 Jul;80(13):6399-410
pubmed: 16775328
Retrovirology. 2012 Jul 17;9:57
pubmed: 22805180
J Antimicrob Chemother. 2016 Jun;71(6):1632-6
pubmed: 26888910
Sci Transl Med. 2012 May 30;4(136):136ra69
pubmed: 22649090
J Antimicrob Chemother. 2016 Sep;71(9):2646-50
pubmed: 27287235
Antimicrob Agents Chemother. 1999 Apr;43(4):802-12
pubmed: 10103184
J Antimicrob Chemother. 2016 Apr;71(4):1046-50
pubmed: 26712907
J Virol. 2002 Jun;76(12):6083-92
pubmed: 12021341
J Acquir Immune Defic Syndr. 2016 May 1;72(1):e12-4
pubmed: 27097366
ILAR J. 2013;54(2):196-210
pubmed: 24174442
Lancet. 2013 Aug 24;382(9893):700-8
pubmed: 23830355
J Virol. 2007 Aug;81(16):8827-32
pubmed: 17537848
Clin Infect Dis. 2018 May 17;66(11):1689-1697
pubmed: 29253097
Tissue Antigens. 1997 Dec;50(6):657-61
pubmed: 9458122
J Infect Dis. 2018 Jul 24;218(5):698-706
pubmed: 29617824
Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):E3413-22
pubmed: 27247400
J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):900-14
pubmed: 15220696
J Virol. 2003 Feb;77(4):2736-40
pubmed: 12552014
J Virol. 2006 May;80(10):5074-7
pubmed: 16641299
Immunol Lett. 1999 Mar;66(1-3):53-9
pubmed: 10203034
AIDS Res Hum Retroviruses. 2016 Feb;32(2):163-8
pubmed: 26150024
Science. 2016 Oct 14;354(6309):197-202
pubmed: 27738167

Auteurs

Koen K A Van Rompay (KKA)

California National Primate Research Center, University of California, Davis, Davis, California, USA kkvanrompay@ucdavis.edu.
Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California, Davis, Davis, California, USA.

Said Hassounah (S)

McGill University AIDS Centre Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.

Brandon F Keele (BF)

AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.

Jeffrey D Lifson (JD)

AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.

Amir Ardeshir (A)

California National Primate Research Center, University of California, Davis, Davis, California, USA.

Jennifer Watanabe (J)

California National Primate Research Center, University of California, Davis, Davis, California, USA.

Hanh Thi Pham (HT)

McGill University AIDS Centre Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.
Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.

Elena Chertova (E)

AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.

Raymond Sowder (R)

AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.

Jan Balzarini (J)

Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.

Thibault Mesplède (T)

McGill University AIDS Centre Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.
Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.

Mark A Wainberg (MA)

McGill University AIDS Centre Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH